Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiaries obtained China's regulatory approval to conduct clinical trials for five anticancer drugs.
These drugs are SHR-4610, SHR-1826, SHR-A2009, Ruikang Trastuzumab and SHR-8068, according to a Monday filing with the Shanghai bourse.
Shares of the company slid 1% on the Shanghai bourse and rose 1% in Hong Kong.